Thermo Fisher Targets Customer Growth in India Amid Biopharma Research and Manufacturing Surge

Thermo Fisher Scientific is projecting annual customer base growth of 15-20% in India, driven by strong momentum in biopharma research and manufacturing activities. This target underscores India's growing significance in the global pharmaceutical and biotechnology sectors. According to Reuters, Thermo Fisher's India operations are benefiting from increased research and development (R&D) spending by local and international pharmaceutical companies, as well as efforts to expand manufacturing capacities. The company notes that growth will be particularly concentrated in the biopharma segment, with both an increase in customer numbers and an expansion of business volumes with existing clients. Thermo Fisher's India strategy aligns with the country's ambition to become a global hub for pharmaceutical manufacturing. Government policies promoting domestic production and investments in biotechnology are supporting the company's growth expectations. Additionally, increased investments in healthcare infrastructure in the post-pandemic period are sustaining demand for laboratory equipment and consumables. Company officials have indicated that customer growth in India will be positive not only in numerical terms but also in terms of revenue per customer. This could help Thermo Fisher strengthen its market share in the country and achieve long-term sustainable growth. This is not investment advice.